Protocol Ledger

NCT04774809 · Phase II/III · TERMINATED

Assess the Efficacy and Safety of SHR0302 Ointment in Adult Patients With Vitiligo

Interventional Phase II/III clinical trial protocol NCT04774809 sponsored by Reistone Biopharma Company Limited in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-01-29 Enrollment: 75 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04774809
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)75 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04774809
Protocol FieldVerified Registry Value
NCT IdentifierNCT04774809
Consolidated Lead SponsorReistone Biopharma Company Limited
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusTERMINATED
Registered Enrollment75 participants (ACTUAL)
Registered Start Date2020-01-29
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04774809
Hospital Research SiteLocationSite Profile
The First Affiliated Hospital Of Fujian Medical UniversityFuzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI